CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 25 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-04-21 | Atillasoy Ercem | Sale | −1,587 | $5.86 | $9K | 121,563 |
| 2022-04-20 | Sinha Vikas Director | Sale | −1,162 | $6.68 | $8K | 906,633 |
| 2022-04-20 | VAN BEEK JEROEN B Chief Commercial Officer | Sale | −852 | $6.68 | $6K | 404,788 |
| 2022-04-20 | Atillasoy Ercem | Sale | −453 | $6.68 | $3K | 123,150 |
| 2022-04-20 | Hagen Brett R Chief Accounting Officer | Sale | −276 | $6.68 | $2K | 80,368 |
| 2022-03-29 | Tomasello Shawn Director | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2022-03-11 | Hallal David Director | Sale | −25,244 | $7.37 | $186K | 2,147,841 |
| 2022-03-10 | Hallal David Director | Sale | −40,481 | $7.55 | $306K | 2,173,085 |
| 2022-03-02 | VAN BEEK JEROEN B Chief Commercial Officer | Sale | −516 | $9.01 | $5K | 382,384 |
| 2022-02-16 | VAN BEEK JEROEN B Chief Commercial Officer | Sale | −15,322 | $8.32 | $128K | 382,900 |
| 2022-02-10 | Bornstein Jeffrey S Director | Purchase | +5,000 | $8.87 | $44K | 35,197 |
| 2022-01-25 | Atillasoy Ercem | Sale | −4,639 | $8.24 | $38K | 100,347 |
| 2022-01-24 | Hallal David Director | Sale | −17,100 | $8.01 | $137K | 2,213,566 |
| 2022-01-20 | VAN BEEK JEROEN B Chief Commercial Officer | Sale | −4,656 | $8.75 | $41K | 398,222 |
| 2022-01-20 | Hagen Brett R Chief Accounting Officer | Sale | −1,563 | $8.75 | $14K | 63,202 |
| 2022-01-20 | Sinha Vikas Director | Sale | −6,450 | $8.75 | $56K | 858,957 |
| 2022-01-18 | Leen Ann M. Chief Scientific Officer | Grant or award | +23,256 | 51,256 | ||
| 2022-01-18 | Leen Ann M. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +56,744 | 366,344 | ||
| 2022-01-18 | Hagen Brett R Chief Accounting Officer | Grant or award | +17,442 | 80,644 | ||
| 2022-01-18 | Hagen Brett R Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +42,558 | 42,558 |
Page 15 of 27 · 527 trades